BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025

BioAge Labs, Inc. (NASDAQ:BIOA), a clinical-stage biotech innovator, announced today the completion of IND-enabling studies for its groundbreaking oral NLRP3 inhibitor, BGE-102, targeting obesity. The company plans to submit an Investigational New Drug (IND) application by mid-2025, with first Phase 1 single ascending dose (SAD) data expected by year-end.

 BioAge Labs, Inc. (BIOA)’s BGE-102 Shows Potent Weight Loss, Plans IND Submission Mid-2025

A scientist in a lab coat analyzing samples from a petri dish, studying the effects of a potential drug candidate.

BGE-102, an internally discovered compound, is distinguished by its novel binding site, high potency, and brain penetration. In preclinical obesity models, BGE-102 delivered dose-dependent weight loss comparable to leading GLP-1 agonist semaglutide, achieving up to 15% reduction as monotherapy and over 20% when combined with semaglutide. The drug also improved insulin sensitivity and demonstrated a robust safety margin in toxicology studies.

BioAge Labs, Inc. (NASDAQ:BIOA)’s CEO, Kristen Fortney, Ph.D., highlighted BGE-102’s potential as a once-daily oral therapy, either alone or with GLP-1 receptor agonists, by targeting the NLRP3 inflammasome, a key driver of inflammation and metabolic dysfunction in obesity.

Pending IND clearance, BioAge Labs, Inc. (NASDAQ:BIOA) will launch Phase 1 trials, with a Phase 1b proof-of-concept study in obesity planned for late 2026.

While we acknowledge the potential of BIOA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than BIOA  and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.